Hikma Pharmaceuticals
Manufacturing · United Kingdom · 5K - 10K Employees
View Company Info for Free
Overview
Headquarters
1 New Burlington Poland, London, Greater...Phone Number
+44 2073992760Website
www.hikma.comRevenue
$3.2 BillionStock Symbol
HIKIndustry
ZI Rank: 2
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
9
9
1
2
2
2
About Hikma Pharmaceuticals
Established in 1978 and headquartered in London, Hikma Pharmaceuticals is a multinational pharmaceutical company that manufactures branded and non-branded generic and in-licensed pharmaceutical products.Explore more
Hikma Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Hikma Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Hikma Pharmaceuticals recently announced quarterly report
Check if Hikma Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Check out if Hikma Pharmaceuticals is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Hikma Pharmaceuticals
Funding: Get notified immidiatlly once Hikma Pharmaceuticals has new funding data
Click to see if Hikma Pharmaceuticals had a recent Job posting/layoffs
Product Launch: Get notified when Hikma Pharmaceuticals launches new products
Hikma Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Hikma Pharmaceuticals as Masked Content
Find 3 more new buyers
Compare Similar Companies to Hikma Pharmaceuticals
Compare insights from companies similar to Hikma Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Hikma Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Hikma Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Hikma Pharmaceuticals.
Hikma Pharmaceuticals Tech Stack
A closer look at the technologies used by Hikma Pharmaceuticals
See more technologies
Most Recent Scoops
Open Position
Open Position
Open Position
Open Position
Event
Product Marketing, Events, Engineering, Sales, Bioengineering, Laboratory Operations, Pharmaceuticals, Field /Outside Sales, Field Marketing, Manufacturing Operations, Operations
Hikma Pharmaceuticals News & Media
Influential Women Recognizes Baylie Brock for Excellence in Pharmaceutical Quality Control and Analytical Chemistry
HILLIARD, OH, UNITED STATES, June 4, 2026 /EINPresswire.com/ -- Delivering Precision, Compliance, and Innovation in Biotechnology and Pharmaceutical Manufacturing at Hikma Pharmaceuticals Baylie Brock is a dedicated Quality Control Analytical Chemist …Hikma Pharmaceuticals Announces Major Expansion in Ohio, Creating 350 New Jobs and Investing $267 Million
Cleveland and Columbus, Ohio, June 01, 2026 (GLOBE NEWSWIRE) -- COLUMBUS and CLEVELAND, Ohio – Ohio Governor Mike DeWine, along with Hikma Pharmaceuticals, JobsOhio, the City of Bedford, and other state and local partners, today announced plans for a significant expansion of Hikma’s manufacturing operations in Ohio, reinforcing the company’s commitment to the state’s growing pharmaceutical and biomanufacturing industry. A leading U.S. generic medication provider, Hikma will invest a total of $26How The Hikma Pharmaceuticals (LSE:HIK) Narrative Is Shifting After Analyst Valuation Resets
Hikma Pharmaceuticals has seen its model fair value edge from £18.84 to £18.74 per share, alongside reduced Street price targets such as 1,800 GBp from 2,300 GBp and 2,000 GBp from 2,400 GBp. Analysts, including JPMorgan with its Overweight rating and revised targets in the £18.00 to £20.00 range, are reframing the story as a valuation reset rather than a change in their overall view. As you read on, you will see how to interpretHikma Pharmaceuticals PLC (HKMPY) Q4 2025 Earnings Call Prepared Remarks Transcript
Hikma Pharmaceuticals PLC (HKMPY) Q4 2025 Earnings Call February 25, 2026 7:00 PM ESTCompany ParticipantsSaid Darwazah - Chief Executive...
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Hikma Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Established in 1978 and headquartered in London, Hikma Pharmaceuticals is a multinational pharmaceutical company that manufactures branded and non-branded generic and in-licensed pharmaceutical products.... Read More
